Supplementary material for Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis: A Systematic Review and Meta-analysis
Description
This dataset contains supplementary tables and figures supporting the manuscript. Abstract Background: Actinic keratosis (AK) is a common precancerous skin lesion. Current field therapies are limited by prolonged treatment duration and local skin reactions (LSR). Objective: To assess the efficacy and safety of tirbanibulin 1% ointment, a novel short-course treatment for AK. Methods: A systematic review and meta-analysis were performed by searching PubMed, Embase, and Cochrane databases for studies evaluating tirbanibulin. Efficacy outcomes included complete and partial clearance rates, while safety outcomes focused on LSR. Pooled incidence rates and 95% confidence intervals (CI) were calculated using a random-effects model. Results: Eight studies comprising 966 patients were included. The pooled complete clearance rate was 57.6% (95% CI: 45.3–69.1), and partial clearance was 66.9% (95% CI: 50.8–79.8). The most frequent LSR were erythema (86.51%; 95% CI: 71.14-94.35), flaking (64.45%; 95% CI: 47.41-78.48) and crusting (30.80%; 95% CI: 16.33-50.37). Severe reactions occurred in 7.16%, 6.45%, and 1.83%, respectively. Limitations: Key limitations include scarce head-to-head data, limited real-world evidence, incomplete baseline AK severity characterization, and short recurrence follow-up. Conclusion: Tirbanibulin demonstrates significant efficacy with a favorable safety profile. Its short regimen enhances adherence, supporting its role as a first-line therapeutic option for AK.
Files
Institutions
- Faculdade de Medicina de MaríliaSão Paulo, Marília